Clinical Trial Update: Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC) [Phase 1]

View source ↗

Summary

Phase 1 imaging study using 111In-labeled pertuzumab to predict response to trastuzumab in HER2-positive breast cancer; the trial status is terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pertuzumab (Perjeta) (pertuzumab)
• Trastuzumab (Herceptin) (trastuzumab)

Snippet

Sponsor: Ontario Clinical Oncology Group (OCOG) | Conditions: Breast Cancer | Phase 1 | Status: TERMINATED